Nuhou Uea

ʻO ka mea maʻi mua i mālama ʻia i ka hoʻāʻo ʻana no ka rhinosinusitis ma hope o ka ʻoki ʻana

i kakauia ma hoʻoponopono

Ua hoʻolaha ʻo Lyra Therapeutics, Inc. i kēia lā ua mālama ʻia ka mea maʻi mua ma ka ʻāpana 1/non-randomized ʻāpana o ka Phase 2 BEACON clinical trial o LYR-220 i nā poʻe maʻi makua me ka rhinosinusitis maʻi (CRS) i loaʻa i kahi ʻoki kino mua. Hoʻolālā kūikawā ʻia ʻo LYR-220 e hāʻawi i nā mahina ʻeono o ka lāʻau anti-inflammatory mau i ke ʻano hoʻomalu a paʻa mau i nā ʻaoʻao sinonasal no nā miliona o nā maʻi CRS e hoʻomau nei e koi i ka mālama ʻana me ka hana ʻana ma mua. Manaʻo ʻia nā hopena kiʻekiʻe mai ka Māhele 1 o ka Phase 2 BEACON i ka hopena o ka makahiki.      

"Ua kaupalena mākou i nā koho lapaʻau pinepine ʻole e hoʻohaʻahaʻa i nā hōʻailona hoʻomau, kaumaha i nā maʻi CRS i hana mua ʻia," wahi a Anders Cervin, MD, PhD, Professor Chair ma Otolaryngology ma ka Center for Clinical Research, Royal Brisbane & Women's Hospital. Campus, Herston, ma Queensland, Australia, a me Principal Investigator ma ke aʻo ʻana o BEACON. "Hiki i ka LYR-220 ke hōʻike i kahi holomua koʻikoʻi i ka mālama ʻana i kēia mau maʻi i mālama ʻole ʻia, ʻo ka hapa nui o lākou ʻaʻole i ʻae ʻia nā koho lapaʻau lāʻau."

ʻO ka hoʻokolohua Phase 2 BEACON kahi haʻawina hui like ʻole e loiloi i ka palekana, ka ʻae ʻana, pharmacokinetics, a me ka maikaʻi e hoʻohālikelike ana i nā hoʻolālā ʻelua o ka LYR-220 (7500µg MF) matrix e hoʻomalu, ma kahi o 24 mau pule, ma kahi o 70 maʻi makua. ʻO nā kumuhana CRS i loaʻa i kahi ʻoki kino bilateral ma mua. Mahele 1 he non-randomized, wehe-lepili haʻawina e loiloi ana i ka feasibility o ka hoonoho ana optimizing kaʻina hana, oiai Part 2 e he maʻi-makapo, 1:1:1 randomized loiloi o elua manao versus sham mana. Manaʻo ka Hui e hoʻopau i ke kākau inoa no ka hoʻāʻo piha ʻana o ka Phase 2 BEACON a puni ka hopena o ka makahiki.

"He mea koʻikoʻi kēia no Lyra i ko mākou holomua ʻana i kā mākou moho huahana CRS lua i ka hoʻomohala ʻana i ka pae hope loa, e hoʻonoho iā mākou i lilo i mea mua e hāʻawi i nā hoʻonā no ka piha piha o nā maʻi CRS i mālama ʻia e nā kauka ENT," wahi a Maria Palasis, PhD. , Peresidena a me Luna Nui o Lyra Therapeutics. "Ke kakali nei mākou i ka holomua ʻana i ka LYR-220 ma o ke keʻena olakino a me ka hoʻohana ʻana i ke ala o LYR-210, kā mākou noiʻi noiʻi no nā maʻi maʻi CRS me ka anatomy surgically-naïve, i kēia manawa i kahi hoʻokolokolo pivotal Phase 3 (ENLIGHTEN I), no nā faila hoʻoponopono e hiki mai ana. ”

Pūnaewele

No ka mea kākau

hoʻoponopono

ʻO Linda Hohnholz ka Lunahooponopono no eTurboNew. Aia ʻo ia ma ka eTN HQ ma Honolulu, Hawaii.

Waiho i ka manaʻo

Kaʻana like i...